Imagen de Portada

Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Joanna Helena Sliwowska, Nicola Elizabeth Woods, Abdullah Rzgallah Alzahrani, Elpiniki Paspali, Rothwelle Joseph Tate, Valerie Anne Ferro
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Journal of Diabetes
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
por: Stergios A. Polyzos, et al.
Publicado: (2026)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
por: Iskandar Idris
Publicado: (2024)

Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
por: Stergios A. Polyzos, et al.
Publicado: (2024)

Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease
por: Jingyuan Ma, et al.
Publicado: (2024)

A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
por: James Kim, et al.
Publicado: (2025)

Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction
por: Jeremy W. Tomlinson
Publicado: (2024)

Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study
por: Jacopo Bonet, et al.
Publicado: (2024)

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
por: Wenxiao Fan, et al.
Publicado: (2025)

Renal lipotoxicity in diabetic and obesity‐associated kidney diseases: Molecular mechanisms and therapeutic targeting
por: Qing Liu, et al.
Publicado: (2025)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
por: Renata Spezani, et al.
Publicado: (2025)

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
por: Michelle D. Lundholm, et al.
Publicado: (2024)

Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study
por: Hai‐Yang Yuan, et al.
Publicado: (2024)

Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
por: Yuqing Ma, et al.
Publicado: (2025)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
por: Claudio Maffeis, et al.
Publicado: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
por: Matthew J. Armstrong, et al.
Publicado: (2024)

O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy
por: Bingxue Qi, et al.
Publicado: (2024)

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
por: Zhuolin Zhou, et al.
Publicado: (2025)

Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features
por: Yahao Wang, et al.
Publicado: (2026)

Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
por: Seoung Hoon Kim
Publicado: (2026)

Clinical utility of liver function tests for resolution of metabolic dysfunction‐associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial
por: S. V. Zhyzhneuskaya, et al.
Publicado: (2024)

Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease
por: Federica Tavaglione, et al.
Publicado: (2024)

The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis
por: Gwyneth Kong, et al.
Publicado: (2024)

Amino acid metabolism modulates chronic kidney disease progression by mediating the aging process: Mechanistic insights and therapeutic interventions
por: Yi Song, et al.
Publicado: (2026)

The role of autophagy in insulin resistance and glucolipid metabolism and potential use of autophagy modulating natural products in the treatment of type 2 diabetes mellitus
por: Xiaoxue Yang, et al.
Publicado: (2024)

High estradiol/testosterone ratio increased the risk of metabolic dysfunction‐associated steatotic liver disease in men with type 2 diabetes mellitus
por: Meng‐Han Li, et al.
Publicado: (2025)

Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
por: Sarra Smati, et al.
Publicado: (2024)

Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type
por: Roberto Franceschi, et al.
Publicado: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
por: Iskandar Idris
Publicado: (2024)

Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment
por: Kevin Yau, et al.
Publicado: (2025)

Reduced insulin clearance in paediatric metabolic (dysfunction)‐associated fatty liver disease and its dual role in beta‐cell offload and diabetes risk
por: Li Jiang, et al.
Publicado: (2024)

Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction‐associated fatty liver disease: A cross‐sectional study of NHANES 2017–2018
por: Zhiliang Mai, et al.
Publicado: (2024)

Emotional distress as a therapeutic target against persistent poor glycaemic control in subjects with type 1 diabetes: A systematic review
por: Sylvia Franc, et al.
Publicado: (2025)

High‐intensity interval training induces lactate dehydrogenase B lactylation to inhibit hepatic lipogenesis to alleviate metabolic dysfunction‐associated fatty liver disease
por: Wenhua Huang, et al.
Publicado: (2026)

Association of overweight/obesity and overweight/obesity‐related metabolic dysfunction‐associated steatotic liver disease in young adults with coronary artery calcification later in life
por: Jia‐Jie Wang, et al.
Publicado: (2024)

Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
por: Xiao‐Dong Zhou, et al.
Publicado: (2024)

A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients
por: Tingting Li, et al.
Publicado: (2025)

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
por: Jonathan Brix Winther, et al.
Publicado: (2024)

Optogenetic therapeutic strategies for diabetes mellitus
por: Xin Deng, et al.
Publicado: (2024)

G3BP1 , a stress granule core protein, ameliorates metabolic dysfunction‐associated fatty liver disease by attenuating hepatocyte lipid deposition
por: Xingjing Liu, et al.
Publicado: (2025)

Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
por: Tsung‐Hua Shen, et al.
Publicado: (2024)